Amid little consensus on the best strategy to defend against the Delta variant of the coronavirus, Pfizer is making its pitch to the United States government in hope...

The FDA’s reportedly cozy relationship with Biogen ahead of its controversial approval of the drugmaker’s Alzheimer’s disease therapy, Aduhelm, has been at the cente...

In an increasingly crowded heart failure field, Novartis’ Entresto is the undisputed leader, AstraZeneca’s Farxiga is the up-and-coming challenger and Merck and Baye...

Many pursuits have been put on hold during the coronavirus pandemic. But biopharmaceutical innovation isn’t one of them. In 2020, the FDA approved 53 new drugs, the ...

Chicago’s scenic expressway Lake Shore Drive has long been an elite address on the opulent north side of America’s third-largest city. Fifty miles to the northwest...

Level Ex’s latest educational mobile app, the Top Derm game aimed at dermatologists, puts actual skin into a video game. The engaging peer-reviewed video game is d...

Talk about a meager return on investment. Pharma companies spend more than $5 billion on patient support programs every year, but when it comes to uptake, only 3% of...

With the COVID-19 pandemic flagging weaknesses in the world's pharma supply chain, contract manufacturer Recipharm is stepping up to help in Africa. In a bid to gr...

As the lone IL-23 inhibitor approved for psoriatic arthritis, Johnson & Johnson’s Tremfya has established a niche with enticing potential among a field of f...

Novartis’ Adakveo and Global Blood Therapeutics’ Oxbryta started their commercial life in 2019 as novel drugs for sickle cell disease. While physicians like their ef...